基本信息
浏览量:65
职业迁徙
个人简介
Key opinion Leader if the field of cancer immunology with over 100 peer-reviewed publications, I have identified the adenosine-producing enzyme CD73 as a novel cancer target (Stagg, PNAS, 2010) and I participated in the development of several adenosine-targeting agents now in clinical trials. My work was also the first to demonstrate that trastuzumab (Herceptin) mediates its activity via adaptive T cell responses and synergizes with anti-PD-1 therapy (Stagg, PNAS, 2011). This led to approval of pembrolizumab (anti-PD-1) in combination with trastuzumab and chemotherapy for first-line treatment of advanced HER2-positive gastric or gastroesophageal adenocarcinoma. My lab is now focused at developing 'next-generation' of cancer immunotherapeutics.
研究兴趣
论文共 164 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Journal of translational medicineno. 1 (2023): 1-16
引用0浏览0WOS引用
0
0
crossref(2023)
biorxiv(2023)
Martin Turcotte,Kathleen Spring,Sandra Pommey, Guillaume Chouinard,Isabelle Cousineau,Joshy George, Gregory M. Chen,Deena M.A. Gendoo, Benjamin Haibe-Kains,Thomas Karn,Kurosh Rahimi,Cécile Le Page,
crossref(2023)
Michael C Warren,Stephan Matissek,Matthew Rausch,Marisella Panduro, R J Hall,Austin Dulak, David Brennan, Sonia Das Yekkirala,Secil Koseoglu,Ricard Masia, Yu Yang, Navamallika Reddy,
ImmunoHorizonsno. 5 (2023): 366-379
2023 IEEE International Ultrasonics Symposium (IUS)pp.1-2, (2023)
引用0浏览0EIWOS引用
0
0
Shayna E.A. Street,Nadeen Zerafa,Manuela Iezzi,Jennifer A. Westwood,John Stagg, Piero Musiani,Mark J. Smyth
crossref(2023)
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn